Loading...
Peginesatide was approved for the treatment of anemia in patients with renal disease in 2012. Studies demonstrated that the agent was as effective as erythropoietin, but cardiovascular adverse events were more common (NEJM JW Oncol Hematol Jan 23 2013).
Between July 2012 and February 2013, 61,482 doses of peginesatide were given to 19,540 patients. Eleven patients experienced severe anaphylaxis and hypotension, 5 of whom died; an additional 17 patients had milder anaphylaxis and hypotension. The drug has been recalled by the manufacturer.
Bennett CL et al. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med 2014 May 22; 370:2055. (http://dx.doi.org/10.1056/NEJMc1400883)
Comment
Peginesatide had the advantage of once-monthly administration, but the unpredictable nature and the severity of its adverse effects led to its withdrawal. Erythropoietin and darbepoietin remain the standard of care for the anemia of chronic kidney disease.